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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
“Does a structured exercise intervention of at least ten weeks improve the distance 
walked in a 6 minute walking test (6MWT) in patients with pulmonary arterial 
hypertension currently on optimized medical control compared to patients who do not 
exercise?” 
STUDY DESIGN: Systematic review of two randomized controlled trials and a 
prospective case study published between 2006-2013, all English language.  
DATA SOURCES: Two randomized controlled studies and a prospective uncontrolled 
trial which studied the effects of a structured exercise program of at least 10 weeks 
duration were obtained using PubMed. 
OUTCOMES MEASURED: The outcome of each study was the distance (measured in 
meters) that each patient was able to walk during the 6 minute walking test as compared 
to their baseline at the beginning of the study. The average of these participants were then 
used to compare the control group versus the intervention group 
RESULTS: Two randomized controlled trials and a uncontrolled prospective study were 
used in this review.  Mereles et al showed a difference between the control and exercise 
group to be a mean of 111 m (95% CI, 65 to 139; P<0.001) after 15 weeks.  Chat et al 
found that there was a statistically significant mean increase of 45m with a 95% CI of 9-
80m (p=0.003) in the exercise intervention group, and determined the number needed to 
treat was 3 using dichotomous data.  Grunig et al showed a significant mean increase 
from baseline to 3-week testing (64 +/- 47m, p<0.001) and again from baseline to 15-
week (71 +/- 35m, p<0.003), with no control group studied. 
CONCLUSIONS: All three studies demonstrated statistically significant improvement in 
the distance walked in the six minute walking test after a structured exercise intervention 
as compared to baseline testing, as well as compared to a control group.  A structured 
exercise intervention in patients with pulmonary arterial hypertension should be 
considered as a useful addition to medical therapy. 
KEY WORDS: pulmonary hypertension, exercise therapy, rehabilitation
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INTRODUCTION 
While treating patients, it is often difficult to avoid frustration by the patient and 
the provider when mainstay therapy does not return the patient to the level of function 
which they desire.  This is often the case with pulmonary arterial hypertension (PAH) 
because it is not curable1, and the effects on a patient’s lifestyle can be devastating. PAH 
is a chronic sustained elevated blood pressure in the pulmonary arteries, which leads to 
stiffening of the pulmonary vasculature.1 
The signs and symptoms of PAH may include dyspnea, chest pain, dizziness, 
syncopal episodes, fatigue, peripheral edema, and a dry cough.2  Patients experiencing 
symptoms at rest indicate severe disease.2  The New York Heart Association Functional 
Classes are useful in categorizing patients because of the similarity of the symptoms 
which are experienced in PAH.3 The NYHA functional classes are graded from I-IV 
depending on severity of symptoms.3  There are several risk factors for developing PAH, 
including female gender, family history, obstructive sleep apnea, pregnancy, living at 
higher altitude, certain drugs such as methamphetamines, and other diseases such as 
congenital heart disease, scleroderma, and lupus.2  The etiology for patients with PAH 
include idiopathic PAH, hereditary PAH, or PAH due to diseases that localize to small 
pulmonary arterioles, such as connective tissue diseases, HIV infection, portal 
hypertension, congenital heart disease, schistosomiasis, and drug use.2 
Although PAH is a relatively uncommon condition, with an estimated prevalence 
of 12.4 cases per 1 million people in the United States and new diagnoses of 2.3 cases per 
1 million, the severity of patient’s symptoms generally lead to a long hospitalizations and 
crippling medical expenses.4 The average cost for the initial hospitalization for a patient 
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with PAH was $30,286 with an average length of stay of 11 days.4  It is often difficult to 
avoid the initial hospitalization since the condition and diagnosis is unknown to the 
patient; however, once the diagnosis of PAH is made, proper medical management can 
help to avoid subsequent admissions.   The average cumulative cost per a rehospitalized 
patient with PAH was $71,622, with an average length of stay of 24.5 days.4 
The currently accepted therapies for PAH include calcium channel blockers, 
digoxin, loop diuretics, home oxygen, and Coumadin2.  Additional medical therapy 
options include endothelin receptor agonists, phosphodiesterase inhibitors, prostacyclins, 
and lung transplant in selected patients.2  Since PAH is not a curable condition, the goal 
of treatment is to minimize patient’s symptoms and reduce the need for hospital 
readmission.  It was previously believed that exercise training would cause an increased 
risk for sudden cardiac death in patients with PAH due to the sheer force on the 
pulmonary arteries during exercise; however, recent studies in patients with left sided 
heart failure have demonstrated the safety of exercise and have broken new grounds in 
the ability to study exercise interventions in patients with chronic cardiopulmonary 
disease.5  This systematic review will utilize two randomized controlled trials and an 
uncontrolled prospective study evaluating the effect of a structured exercise intervention 
on distance walked on a 6 minute walking test in patients with pulmonary arterial 
hypertension currently on optimized medical therapy. 
OBJECTIVE 
Does a structured exercise intervention of at least ten weeks improve the distance 
walked in a 6 minute walking test (6MWT) in patients with pulmonary arterial 
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hypertension currently on optimized medical control compared to patients who do not 
exercise? 
METHODS 
This systematic review will study the population of patients that are between the 
ages of 18-80, who have previously been diagnosed with pulmonary arterial hypertension and are 
currently on optimized medical therapy.  The intervention being reviewed in this study is a 
structured exercise intervention of at least 10 weeks duration.  The comparison group was 
patients with pulmonary arterial hypertension on current optimized medical control without a 
structured exercise intervention.  The outcome that was measured was the distance walked in the 
6MWT after exercise intervention as compared to baseline 6MWT.  Two randomized 
controlled studies were used for analysis, as well as a prospective case study. 
The key words used in the searches were “pulmonary hypertension,” “exercise 
therapy,” and “rehabilitation.” All articles were originally published in peer reviewed 
journals in the English language. The author searched articles via PubMed and Cochrane 
library, and articles were selected based on their relevance to the clinical question.  
Inclusion criteria consisted of studies which were published after 1999. Exclusion criteria 
consisted of studies which had patients who were under the age of 18 or over the age of 
80, or patients who had changed their medications used to control PAH within the 
previous two months.   The statistics of this study were analyzed using mean change from 
baseline, NNT, p-values and 95% confidence interval. 
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Table 1 - Demographics & Characteristics of included studies  
Study Type 
# of 
pati
ents Age 
Inclusion 
Criteria 
Exclusion 
Criteria 
W
/
D Interventions 
Merel
es, 
2006 
(5) 
RCT, 
cross
over 
single 
blind
ed 
study 
32 18-75 yo 
Three months 
of optimized 
medical 
therapy, WHO 
functional 
class II-IV 
Active 
lifestyle.  
Recent 
syncopal 
episode.  
Physical 
ailment 
preventing 
exercise.  
Medication 
changes in 
previous 3 
months. 
2 
Inpatient exercise program 
for 3 weeks which 
includes: bicycle ergometer 
for 10-25 minutes per day, 
60 minutes of walking 
preformed 5 days per 
week.  5 days per week of 
30 minute of resistance 
training, and 30 minutes of 
respiratory training 
Patients continued cardio 
and resistance training at 
home for 12 weeks 
following inpatient stay. 
Chan, 
2013  
(6) 
Phase 
2b 
RCT, 
single 
blind
ed 
26 21-82 yo 
Pulmonary 
arterial 
pressure 
greater than 25 
mmHg. WHO 
functional 
classes II-III.  
Optimized 
medical 
therapy 
Medication 
change in 
previous 
three 
months.  
Active 
lifestyle.  
Illicit drug 
use, 
tobacco 
use, or 
pregnancy. 
3 
24-30 sessions of 
medically supervised 
treadmill walking for 30-45 
minutes per session over 
the course of 10 weeks.  
Target heart rate intensity 
ranged from 70-80% from 
baseline maximums.  
Experimental group also 
received weekly 
educational classes. 
Gruni
g, 
2012 
(7)  
Prosp
ective 
Case 
Study 
22 18-80 yo 
WHO Class II-
IV, optimized 
medical 
therapy  
Any 
change in 
medication 
within the 
previous 
two 
months. 
1 
Exercise therapy consisted 
of interval bicycle 
ergometer training at low 
workloads, mental gait 
training, dumbbell-training 
of single muscle groups 
using low weights (500 to 
1000 g) and respiratory 
therapy 5 days/week. The 
training was continued at 
home with at least 30 
minutes/day at 5 days/week 
for the following 12 weeks. 
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OUTCOMES MEASURES 
Two randomized controlled studies and an uncontrolled prospective study were 
used in this review and the outcome which was measured was patient oriented (POEM).  
The outcome that was measured for this review was the distance (measured in meters) 
that each patient was able to walk during the 6 minute walking test with a standard 
deviation presented as (+/-), as compared to baseline at the beginning of the study. The 
average of these participants were then used to compare the control group versus the 
intervention group.   
RESULTS 
The study conducted by Mereles et al was a prospective randomized trial which 
consisted of thirty patients with PAH, randomized into a control group (n=15), and a 
treatment group (n=15).  The intervention in this study was a structured exercise 
intervention of three weeks duration in a hospital, followed by 12 additional weeks of self 
guided training.  The 6MWT was completed pre-intervention, at 3 weeks, and at 15 
weeks, and the control group was allowed to cross over to the treatment group at the end 
of week 15 (n=10).5     
The initial control group and intervention group did not vary significantly in the 
6MWT at baseline.  After 3 weeks of treatment, the 6MWT increase was significantly 
larger in the intervention group (85+/- 56 m) than in the control group (12 +/- 37 m; 
P=0.0003).5 After 15 weeks, the 6MWT decreased in the control group (-15 +/- 54 m), 
whereas patients in the primary training group revealed a further improvement (96+/- 61 
m; P<0.0001).5   The difference between groups was a mean of 111 m (95% CI, 65 to 
139; P<0.001).5  Patients in the crossover group improved similarly to the patients in the 
initial intervention group, showing a significantly higher increase in the 6MWT after 3 
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weeks (75 +/- 41 m, p<0.05) and after 15 weeks (mean 74 +/- 49 m, p<0.001) compared 
with baseline.5  Overall, the treatment increased walking distance in the 6MWT by an 
average of 96 m, an increase of 22%, when combining the data from the primary exercise 
group and the crossover group.5  Individual patient data was not available to calculate 
numbers needed to treat.  P-values of less than 0.05 were considered significant.  The 
data in Tables 2-4 is provided from Mereles et al. 
Table 2 –Comparison of Control Group vs Exercise Intervention after 3 and 15 weeks 5 
  Baseline 6MWT (m) 
3 week 6MWT 
change from baseline 
(m) 
15 week 6MWT 
change from baseline 
(m) 
Control (n=15) 411 +/- 86 12 +/- 37  -15 +/- 54 
Exercise 
Intervention 
(n=15) 
439 +/- 52 85 +/- 56 96 +/- 61 
p-value 0.38 0.003* <0.0001* 
 
Table 3 –Mean Difference, Confidence Interval, and P-value for Control vs Intervention5 
Mean difference after 15 weeks (m) 95% CI (m) p-value 
111 65-139  <0.001* 
 
Table 4 –Crossover Intervention Group Change from Baseline5 
  
3 week 6MWT change from 
baseline (m) 
15 week 6MWT change from 
baseline 
Crossover exercise 
group (n=10) 
75 +/- 41 74 +/- 49 
p-value <0.05* <0.001* 
 
 
Chan et all conducted a randomized controlled trial which originally consisted of 
twenty-six patients, divided into a treatment group (n=10) which received education and 
a ten week exercise intervention and a control group (n=13) which only received 
education.  The intervention group had three patients eliminated from the trial before 
analysis of the data, two patients due to changes in medications, and one because of less 
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than 80% compliance with the exercise regimen.6  The 6MWT was completed at 
baseline, and again at week ten. 
At baseline, there was no significant difference between the interventional 
(mean=411 +/- 73m) and control group (377 +/- 97m) in the 6MWT (p=0.183).6  The 
intervention group showed a significant increase in distance walked after ten weeks of 
training to 467 +/- 86m, with a p value of 0.002 compared to baseline.6  The control 
group did not demonstrate a statistically significant increase in distance walked, with ten-
week results at 389 +/- 107m with a p value of 0.134 as compared to baseline.  The 
difference between the groups was statistically significant, with a mean distance of 45m, 
95% CI 9-80m, and a p value of 0.008.6  Using a significant improvement of greater than 
or equal to 41m per individual, the results of the study was converted to dichotomous 
data and was used to measure the numbers needed to treat (NNT=3).  The data in Tables 
5-7 is provided from Chan et al. 
Table 5 – Baseline and 10-week 6MWT data for Control and Exercise Intervention6 
  
Baseline 6MWT 
(m) 
10 week 6MWT 
(m) p-value 
Control Group 
(n=13) 377 +/- 97 389 +/- 107 0.134 
Exercise Intervention 
Group (n=10) 
411 +/- 73 467 +/- 86 0.002* 
p-value 0.183 - - 
 
Table 6 – Mean Difference, Confidence Interval, and p-value for Exercise Intervention6 
Mean Difference (m) 95% CI p-value 
45 9-80m 0.008 
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Table 7 – Calculation of Numbers Needed to Treat6 
    
Relative 
Benefit 
Increase (RBI) 
Absolute 
Benefit 
Increase (ABI) 
Number Needed 
to Treat (NNT) 
CER EER (EER - CER) / CER EER-CER 1/ABI 
3/13 = 23.1% 6/10 = 60% 1.6 0.369 2.71 = 3 patients 
 
Grunig et al conducted a prospective, uncontrolled trial utilizing the same 
methods as Mereles et al; however, there was no control group.  There were initially 22 
patients in the trial; however, one patient dropped out of the study due to an upper airway 
infection.  The baseline average distance walked in the 6MWT was 386 +/- 121m.  After 
3 weeks, the mean distance walked increased significantly by 64 +/- 47 meters (P < 
0.001) and by 71 ± 35 meters after 15 weeks (P < 0.003).7  Only one patient in the trial 
did not show an increase in distance walked from baseline, likely due to hip 
osteoarthritis.7  Nine patients were lost to follow up at 15 weeks, likely due to distance 
needed to travel to complete the study.  Results remained significant after multiple 
imputations of missing values for the 6MWD at 15 weeks using the predictive mean 
managing model.  The data in Table 8 was taken from Grunig et al. 
Table 8 – Mean Distance Walked in 6MWT at Baseline, 3 weeks, and 15 weeks 
  
Baseline 6MWT 
Mean (m) 
Change from Baseline 
at 3 week 6MWT (m) 
Change from Baseline at 
15 week 6MWT (m) 
386 +/- 121 64 +/- 47 71 +/- 35 
p-value - <0.001* <0.003* 
 
DISCUSSION 
 Although each of the three studies in this review demonstrated statistically 
significant improvements from baseline for patients with pulmonary arterial 
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hypertension, there were a few factors that may impact the significance of these studies.  
First, the six-minute walking test has long been thought to be the best test to determine 
the effectiveness of a medical intervention for patients with cardiopulmonary disease; 
however, there are a few critics that suggest that the 6MWT is too short in duration to 
gain any meaningful data for the effectiveness of the trial.8   Since this review is focused 
solely on patient oriented outcomes, this criticism was not taken into account when 
determining significance of this study. 
 Another factor which should be considered is the multiple etiologies of 
pulmonary hypertension.2   These three studies consisted of a heterogeneous group of 
patient with different etiologies for pulmonary hypertension.  Since each of the studies 
demonstrated significant improvement in the 6MWT in the exercise intervention group, it 
could be hypothesized that all etiologies of pulmonary hypertension would benefit from 
an exercise intervention.  Also, patients were taken from all functional classes before 
intervention, thus results cannot be generalized across functional classes.3   Further 
studies with homogenous etiologies of pulmonary hypertension should be considered to 
determine the effectiveness of exercise intervention. 
 Finally, because of the nature of this intense exercise intervention and the 
inpatient component of the program, it may be too expensive to safely provide an 
exercise intervention for patients with pulmonary hypertension.  It is likely that insurance 
companies would not pay for patients to receive long-term inpatient rehabilitation in the 
United States, as well as paying for maintenance therapy once the initial intervention is 
complete6.  If insurance companies will not cover the therapy, it is likely too expensive 
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for patients to consider exercise intervention as a safe method for improvement of 
symptoms of pulmonary hypertension.  
The results of exercise intervention as compared to pharmaceutical treatment for 
pulmonary hypertension suggest that exercise intervention may be more effective in 
improving the 6MWT than drug therapy.  In fact, the treatment-related increase in 
walking distance of 96 m (22%) observed in Mereles et al was higher than the increases 
observed with the use of sildenafil9, oral epoprostenol10, inhaled iloprost11, and oral 
bosentan12. 
There were also a few limitations of these studies as well.  Because of the nature 
of the studies, it was impossible to complete a blinded study with the exercise 
intervention.  This could potentially lead to incentive for extra encouragement for the 
exercise intervention groups.  In addition, there was no control group for the study 
completed by Grunig et al.  Finally, each of the studies had small sample sizes, which 
could have skewed the data.  There were only 74 patients combined in this systematic 
review, with only 28 patients confined to the control groups5,6,7.  To be sure of these 
results, future studies should be designed to attract more patients with pulmonary 
hypertension to participate. 
CONCLUSION 
The findings of these three studies have demonstrated that there is a statistically 
significant increase in distance walked in the six-minute walking test from baseline after 
the conclusion of a structured exercise intervention of at least ten weeks in patients with 
pulmonary arterial hypertension, currently on optimized medical control compared to 
patients who do not exercise5,6,7.  
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Future studies should be conducted to determine the significance of exercise 
intervention for individual etiologies of pulmonary arterial hypertension, as well as the 
effect of exercise intervention on each specific functional class of the disease.  There are 
not any ongoing trials studying exercise intervention in pulmonary arterial hypertension 
at this time. 
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